Brief: Richter-Helm Biologics expands deal to support COVID-19 DNA vaccine trials
April 30 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt
* RICHTER-HELM BIOLOGICS AND INOVIO TO EXPAND EXISTING DNA
MANUFACTURING AGREEMENT TO SUPPORT LARGE-SCALE MANUFACTURING OF
INOVIO'S INVESTIGATIONAL DNA VACCINE FOR COVID-19
* RICHTER SAYS INOVIO'S INO-4800 IS CURRENTLY IN PHASE 1
CLINICAL
TESTING IN THE U.S. AND COULD POTENTIALLY ADVANCE TO PHASE 2/3
EFFICACY TRIALS THIS SUMMER -STATEMENT
Further company coverage: GDRB.BU INO.A INO.O
(Reporting by Gergely Szakacs)
((gergely.szakacs@reuters.com ; https://twitter.com/szakacsg ;
+36 1 882 3606 ;
https://www.reuters.com/journalists/gergely-szakacs))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab